- Business Wire•2 hours ago
Teva Pharmaceutical Industries Ltd. today announced that it has received a positive outcome through the variation procedure to remove the pregnancy contraindication from the European label for COPAXONE® 20 mg/mL.
- Investor's Business Daily•10 hours ago
TherapeuticsMD surged late Monday after saying that its menopause drug reduced hot flashes and other vasomotor symptoms in a late-stage trial.
- Reuters•10 hours ago
Teva Pharmaceutical Industries , the world's biggest generic drugmaker, has appointed Dipankar Bhattacharjee as chief executive for its global generic medicines group, replacing Siggi Olafsson. Bhattacharjee, who has served as CEO of Teva Generics Europe since April 2013, will replace Olafsson, who will retire at the end of the first quarter of 2017. Bhattacharjee will be based in the United States.
TEVA : Summary for Teva Pharmaceutical Industries - Yahoo Finance
Teva Pharmaceutical Industries Limited (TEVA)
NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
|Bid||35.70 x 900|
|Ask||35.76 x 2600|
|Day's Range||36.40 - 37.18|
|52 Week Range||36.40 - 66.55|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||21.55|
|Dividend & Yield||1.36 (3.72%)|
|1y Target Est||N/A|